Therapy resistance in cancer, DNA damage and repair, epigeneitcs, glioblastoma, leukemia
Our laboratory is interested in understanding the molecular mechanisms of resistance, the most germane and fundamental issue in the cancer therapeutics with a particular focus on DNA repair pathways and their epigenetic regulation. We take the multi-pronged approach employing molecular biology, cell biology, genomics and proteomics to answer some of the basic questions pertaining to chemo and radiation resistance. Using clinically relevant patient samples and patient-derived cellular and mouse models developed in our lab, we have identified novel and targetable molecular pathways employed by leukemic and glioblastoma cells to acquire resistance and relapse. We collaborate with the clinicians at ACTREC and TMH to translate the basic research findings into clinics.
Resistance to radiation is a major challenge in the treatment of Glioblastoma. A subset of tumor cells is capabl… more
Cellular signalling is complex network of many signalling pathways coordinating together. To get a comprehensive… more
There is now compelling evidence for tumour initiating or cancer stem cells (CSCs) in human cancers. Inherent in… more
Barreto SG, Gardi N, Dutt S.
Gardi N, Ketkar M, McKinnon R, Pandol S, Dutt S, Barreto S
Yadav N, Rajendra J, Acharekar A, Dutt S, Vavia P
Kaur E, Nair J, Ghorai A, Mishra SV, Achareker A, Ketkar M, Sarkar D, Salunkhe S, Rajendra J, Gardi N, Desai S, Iyer P, Thorat R, Dutt A, Moiyadi A, Dutt S